Evidence map›Paper›PMID 36422298›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

The Association of Metformin, Other Antidiabetic Medications, and Statins With the Prognosis of Colon Cancer in Patients With Type 2 Diabetes: A Retrospective Cohort Study.

Sami Erkinantti, Ari Hautakoski, Reijo Sund, Martti Arffman, Elina Urpilainen, Ulla Puistola, Arja Jukkola, Karihtala Peeter, Esa Läärä

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Sami ErkinanttiDepartment of Oncology and Radiotherapy, 577217Medical Research Center Oulu, 60664Oulu University Hospital6370and University of Oulu, Oulu, Finland.ORCID 0000-0003-2538-2941
Ari HautakoskiDepartment of Obstetrics and Gynecology, PEDEGO Research Unit, 577217Medical Research Center Oulu, 6370University of Ouluand University Hospital of Oulu, Oulu, Finland.
Reijo SundInstitute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.ORCID 0000-0002-6268-8117
Martti ArffmanDepartment of Public Health and Welfare Finnish Institute for Health and Welfare, Helsinki, Finland.ORCID 0000-0002-1647-4783
Elina UrpilainenDepartment of Obstetrics and Gynecology, PEDEGO Research Unit, 577217Medical Research Center Oulu, 6370University of Ouluand University Hospital of Oulu, Oulu, Finland.
Ulla PuistolaDepartment of Obstetrics and Gynecology, PEDEGO Research Unit, 577217Medical Research Center Oulu, 6370University of Ouluand University Hospital of Oulu, Oulu, Finland.
Arja JukkolaDepartmentof Oncology and Radiotherapy, Tampere University Hospital, Cancer Center Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Karihtala PeeterDepartment of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.
Esa LääräResearch Unit of Mathematical Sciences, University of Oulu, Oulu, Finland.
Oulu University Hospital · FIFinnish Institute for Health and Welfare · FITampere University Hospital · FIUniversity of Eastern Finland · FIUniversity of Helsinki · FIUniversity of Oulu · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUse of metformin and statins have been associated with improved prognosis of colon cancer (CC) in patients with type 2 diabetes (T2D). We examined the survival from CC in relation to the use of metformin, other oral antidiabetic medications (ADM), insulin, and statins in T2D patients. MATERIALS AND

methodsA cohort (n = 2252) of persons with pre-existing T2D diagnosed with incident CC between 1998 and 2011 was identified from several Finnish registers. Cox models were fitted for cause-specific mortality rates to obtain adjusted estimates of the hazard ratios (HR) with 95% confidence intervals (CI) in relation to use of ADM and statins before the CC diagnosis. Cox models were also fitted for mortality in relation to post-diagnostic use of the medications treating these as time-dependent exposures, and starting follow-up 1 year after the CC diagnosis.

resultsPre- and post-diagnostic metformin use was weakly associated with the risk of CC-related death (HR .75; 95% CI .58-.99, and HR .78; 95% CI .54-1.14, respectively) compared to the use of other oral ADMs. Pre- and post-diagnostic statin use predicted a reduced risk of CC-related death (HR .83; 95% CI .71- .98, and HR .69; 95% CI .54-.89, respectively).

conclusionAdditional evidence was found for use of statins being associated with an improved survival from CC in patients with pre-existing T2D, but for metformin use the evidence was weaker.

Indexed as

Colonic NeoplasmsDiabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsMetforminCohort StudiesHumansHypoglycemic AgentsPrognosisRetrospective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMetformincolorectalinsulinmalignancymortalitysurvival

Identifiers

PMID36422298
PMCPMC9703554
OpenAlexW4310459749

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.